Icosavax buy­out caps As­traZeneca’s long search for a vac­cine plat­form

As­traZeneca is gain­ing a late-stage RSV vac­cine can­di­date as part of its pro­posed ac­qui­si­tion of Icosavax af­ter the British drug­mak­er spent two years search­ing for a plat­form that would help de­fine the di­vi­sion that en­com­pass­es its vac­cine and an­ti­bod­ies busi­ness­es.

The com­pa­ny has been “dili­gent­ly look­ing at all dif­fer­ent plat­forms” in a “rel­a­tive­ly broad” ef­fort since launch­ing the busi­ness unit in late 2021, said Iskra Re­ic, the ex­ec­u­tive vice pres­i­dent who leads As­traZeneca’s vac­cines and im­mune ther­a­pies unit, in an in­ter­view with End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER